BIO Stock Cash Flow Statements

Bio-Rad Laboratories Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Bio-Rad Laboratories Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30

cash flows from operating activities:
cash received from customers	664,900,000	640,000,000	632,115,000	655,532,000	627,129,000	638,324,000	676,766,000	647,276,000	682,684,000	677,522,000	717,449,000	658,079,000	673,880,000	649,993,000	709,290,000	720,598,000	728,588,000	728,013,000	789,704,000	614,290,000	558,140,000	569,001,000	595,439,000	573,264,000	592,931,000	550,291,000	610,350,000	555,056,000	571,035,000	589,869,000	575,029,000	519,140,000	490,797,000	508,982,000	543,419,000	510,456,000	527,742,000	492,407,000	512,412,000	472,056,000	493,137,000	478,479,000	548,797,000	526,236,000	543,040,000	544,447,000	558,779,000	524,906,000	502,187,000	504,158,000	550,814,000	504,476,000	507,440,000	501,075,000	509,821,000	488,652,000
cash paid to suppliers and employees	-505,900,000	-488,000,000	-526,870,000	-446,405,000	-524,609,000	-560,316,000	-518,313,000	-548,888,000	-620,295,000	-552,990,000	-596,793,000	-610,084,000	-581,357,000	-619,809,000	-542,944,000	-466,405,000	-518,730,000	-612,803,000	-480,561,000	-447,127,000	-449,617,000	-509,683,000	-425,922,000	-460,644,000	-424,849,000	-507,160,000	-494,891,000	-487,229,000	-463,865,000	-543,700,000	-485,547,000	-463,308,000	-419,160,000	-550,956,000	-445,296,000	-429,961,000	-426,767,000	-508,820,000	-451,807,000	-379,498,000	-444,771,000	-453,986,000	-453,872,000	-434,502,000	-450,051,000	-468,101,000	-466,262,000	-420,625,000	-451,134,000	-459,667,000	-429,669,000	-396,363,000	-406,441,000	-428,733,000	-406,793,000	-406,844,000
interest paid	-900,000	-22,200,000	-872,000	-22,327,000	-876,000	-22,425,000	-1,095,000	-22,859,000	-1,053,000	-22,482,000	-461,000	-23,534,000	-134,000	-306,000	-403,000	-312,000	-1,227,000	-309,000	-10,573,000	-219,000	-10,616,000	-231,000	-10,949,000	-296,000	-10,626,000	-459,000	-10,982,000	-444,000			-10,552,000	-257,000			-10,123,000	-284,000			-11,173,000	-549,000			-10,036,000	155,000	-10,620,000	-292,000	-11,045,000	-25,507,000	-13,006,000	-11,675,000	-10,440,000	-11,828,000	-11,761,000	-12,340,000	-10,773,000	-12,790,000
income tax payments	-48,200,000	-7,900,000	-23,690,000	-23,538,000	-48,337,000	-3,835,000	-88,627,000	-9,410,000	-18,273,000	-13,283,000	-20,396,000	-51,708,000	-71,831,000	-14,324,000	-30,781,000	-26,329,000	-62,846,000	-14,727,000	-13,705,000	-41,534,000	-5,477,000	-4,528,000	-2,447,000	-18,618,000	-19,449,000	-4,567,000	-4,574,000	-10,220,000	-44,375,000	-3,245,000	-12,315,000	-20,755,000			-1,069,000	-26,288,000			-16,069,000	-9,377,000			2,166,000	-14,046,000	-10,150,000	-6,909,000	-11,424,000	-17,618,000	-27,907,000	-14,195,000	-13,650,000	-26,165,000	-22,609,000	-25,010,000	-14,102,000	-19,320,000
dividend proceeds and miscellaneous receipts	32,600,000	16,300,000	18,907,000	16,096,000	35,262,000	15,835,000	18,273,000	16,406,000	50,760,000	14,662,000	17,038,000	9,439,000	21,027,000	20,680,000	11,063,000	1,926,000	10,100,000	12,193,000
proceeds from (payments for) forward foreign exchange contracts	-26,000,000	-8,300,000		-15,748,000	9,077,000	2,209,000			4,243,000	-5,310,000																342,000	324,000	1,867,000													42,000	3,016,000					502,000
net cash from operating activities	116,500,000	129,900,000	124,152,000	163,610,000	97,646,000	69,792,000	81,047,000	97,711,000	98,066,000	98,119,000	90,420,000	7,514,000	50,198,000	46,315,000	157,924,000	230,363,000	154,624,000	113,610,000	284,734,000	135,664,000	92,122,000	62,808,000	159,802,000	99,750,000	155,402,000	42,943,000	105,009,000	62,277,000	77,862,000	40,346,000	69,354,000	28,331,000	62,420,000	-56,220,000	95,119,000	51,607,000	77,155,000	-7,448,000	35,952,000	82,279,000	38,533,000	29,446,000	40,216,000	83,272,000	80,903,000	68,921,000	73,441,000	62,847,000	18,688,000	20,500,000	98,654,000	71,342,000	73,642,000	35,260,000	78,577,000	51,158,000
cash flows from investing activities:
payments for purchases of property, plant and equipment	-45,700,000	-34,400,000	-42,914,000	-40,229,000	-42,281,000	-40,176,000	-42,245,000	-44,071,000	-34,639,000	-35,725,000	-45,558,000	-24,062,000	-14,263,000	-28,899,000
proceeds from dispositions of property, plant and equipment			-49,000	57,000	66,000	26,000	107,000	65,000			47,000	6,000			0	39,000	1,000	12,000	19,000	18,000	-5,000	38,000	44,000	-1,000	12,000	74,000	42,000	173,000	4,082,000	18,000	24,000	41,000	6,000	15,000	20,000	357,000	20,000	1,000	38,000	12,000	25,000	4,000	-156,000	43,000	224,000	114,000	-38,000	164,000
payments for acquisitions, net of cash received											0									234,000						-16,083,000
payments for purchases of marketable securities and investments	-153,200,000	-153,400,000	-222,940,000	-399,119,000	-248,083,000	-406,458,000	-151,501,000	-196,018,000	-137,934,000	-203,588,000	-253,090,000	-328,716,000	-517,492,000	-960,940,000	-391,566,000	-204,784,000	-180,352,000	-74,925,000	-63,792,000	-12,002,000	-74,512,000	-98,151,000	-104,611,000	-95,224,000	-76,240,000	-95,375,000	-84,193,000	-103,825,000	-121,558,000	-61,443,000	-48,890,000	-90,773,000	-74,688,000	-68,305,000	-60,251,000	-69,397,000	-76,938,000	-71,485,000	-122,057,000	-61,148,000	-44,724,000	-66,568,000	-46,139,000	-60,534,000	-53,800,000	-45,273,000	-61,678,000	-48,201,000	-129,864,000	-146,971,000		-144,721,000
proceeds from sales of marketable securities and investments	274,400,000	171,200,000	205,507,000	363,949,000	205,081,000	331,463,000	162,906,000	143,101,000	103,181,000	92,751,000	165,575,000	229,317,000	281,226,000	32,096,000	370,050,000	22,686,000	17,177,000	15,624,000	13,737,000	13,103,000	23,222,000	39,672,000	21,317,000	33,271,000	27,720,000	22,324,000	16,541,000	25,940,000	17,157,000	17,391,000	13,640,000	44,521,000	19,161,000	20,201,000	17,172,000	17,301,000	22,005,000	20,381,000	22,034,000	15,492,000	13,782,000	27,356,000	17,034,000	13,816,000	20,473,000	24,402,000	12,390,000	178,801,000	38,403,000	60,185,000		40,400,000
proceeds from maturities of marketable securities and investments	25,700,000	19,500,000	29,842,000	43,116,000	54,290,000	72,052,000	100,430,000	87,423,000	97,337,000	76,089,000	65,086,000	139,295,000	107,651,000	45,781,000	89,228,000	135,337,000	86,285,000	30,509,000	35,648,000	109,479,000	65,487,000	67,710,000	45,792,000	42,864,000	55,671,000	82,573,000	66,673,000	70,212,000	42,924,000	45,486,000	50,987,000	52,881,000	47,809,000	50,570,000	40,908,000	38,076,000	28,861,000	35,175,000	49,267,000	44,108,000	36,949,000	40,499,000	20,924,000	29,260,000	48,716,000	21,490,000	41,345,000	67,133,000	90,474,000	77,100,000		61,950,000
net cash from investing activities	-115,400,000	2,900,000	-30,544,000	-55,636,000	-30,927,000	-43,093,000	72,197,000	-9,500,000	27,984,000	-70,473,000	-69,315,000	-84,906,000	-141,410,000	-911,962,000	-554,484,000	-81,350,000	-100,277,000	-48,327,000	-50,109,000	90,854,000	-88,573,000	-12,422,000	-61,196,000	-109,909,000	-15,071,000	-22,713,000	-54,811,000	-29,509,000	-83,842,000	-18,816,000	-13,083,000	-14,814,000	-37,283,000	-110,392,000	-50,123,000	-53,429,000	-59,470,000	-50,858,000	-83,778,000	-27,235,000	-27,865,000	-27,991,000	-49,444,000	-39,129,000	-63,017,000	-38,921,000	-42,336,000	179,989,000	-27,735,000	-115,339,000	-72,040,000	-103,926,000	-150,553,000	-86,285,000	-169,524,000	-55,813,000
cash flows from financing activities:
payments on long-term debt	-200,000	-100,000
payments for debt issuance costs			17,000	0	0	-617,000
proceeds from issuance of common stock and from reissuance of treasury stock under the employee stock purchase plan and upon exercise of stock options	4,200,000	4,300,000	3,910,000	5,102,000	4,683,000	5,505,000	4,316,000	4,647,000	5,097,000	4,424,000	4,342,000	4,774,000
tax payments from net share settlement			-120,000	-3,128,000			-4,818,000	-9,806,000			-91,000	-13,433,000			-162,000	-21,813,000			-100,000	-5,899,000			0	-4,120,000
payments for purchases of treasury stock	-140,200,000	-101,900,000	-14,000	-97,837,000	-101,000,000	-4,749,000	-200,000,000	-21,321,000			-90,679,000	0			0	0	0	-49,998,000	0	1,000	0	-100,005,000	-8,000,000	-4,999,000							0	-2,037,000
net cash from financing activities	-136,300,000	-97,700,000	-26,248,000	-95,986,000	-96,587,000	21,000	-200,620,000	-26,598,000	-202,738,000	4,309,000	-86,619,000	-8,772,000	-121,326,000	1,190,293,000	4,635,000	-15,582,000	2,865,000	-47,347,000	-421,884,000	439,000	-2,979,000	-98,617,000	-4,783,000	-4,491,000	-15,645,000	2,161,000	-47,003,000	-2,176,000	-2,016,000	2,515,000	3,576,000	-2,840,000	-1,068,000	673,000	2,829,000	2,897,000	3,036,000	258,000	3,728,000	2,123,000	3,061,000	-331,000	3,625,000	1,766,000	2,808,000	3,490,000	3,768,000	-322,403,000	3,790,000	3,148,000	3,515,000	2,554,000	2,800,000	3,719,000	-1,733,000	2,056,000
effect of foreign exchange rate changes on cash	-16,200,000	-1,800,000	10,221,000	-7,515,000	3,831,000	2,663,000	-6,570,000	6,221,000	2,666,000	-1,996,000	-18,186,000	7,501,000	6,789,000	6,877,000	-1,462,000	-6,072,000	2,245,000	-7,347,000	9,273,000	6,012,000	3,119,000	-5,977,000	5,476,000	-5,366,000	145,000	1,982,000	-4,620,000	912,000	4,436,000	-1,383,000	-4,917,000	-3,367,000	5,852,000	1,338,000	-9,500,000	-1,787,000	-5,685,000	4,114,000	-5,682,000	29,000	10,676,000	11,353,000	-5,739,000	-5,986,000	-531,000	-534,000	4,885,000	4,361,000	3,627,000	-3,068,000	6,802,000	0	-3,214,000	6,887,000	-4,117,000	3,326,000
net increase in cash, cash equivalents and restricted cash	-151,400,000	33,300,000	77,581,000	4,473,000	-26,037,000	29,383,000		67,834,000	-74,022,000	29,959,000	-83,700,000	-78,663,000	-205,749,000	331,523,000
cash, cash equivalents and restricted cash at beginning of period	0	489,800,000		0	0	404,369,000		0	0	434,544,000		0	0	471,133,000
cash, cash equivalents and restricted cash at end of period	-151,400,000	523,100,000		4,473,000	-26,037,000	433,752,000		67,834,000	-74,022,000	464,503,000		-78,663,000	-205,749,000	802,656,000
proceeds from forward foreign exchange contracts							-5,957,000							10,081,000				1,243,000				4,337,000																	699,000
proceeds from divestiture of a division											0	0							0	0
payments for acquired in-process research and development			10,000
payments for purchases of intangible assets																											0	0	0	-3,000	-5,000	130,000			-129,000	0			3,000	-54,000	-14,000	-1,307,000	9,000	-106,000	-3,024,000	-12,358,000	-200,000	0	-37,000	-463,000		-491,000
proceeds from issuance of notes, net of debt financing costs											0	0	0	1,186,220,000
payments on long-term borrowings					-118,000	-118,000	-118,000	-118,000	-116,000	-115,000	-143,000	-113,000	-150,000	-104,000	-1,375,000	-122,000	-122,000	-1,401,000	-425,158,000	-183,000	-182,000	-1,415,000	-156,000	-128,000	-122,000	-237,000	-1,366,000	-90,000	-1,418,000	-87,000	-96,000	-71,000	-73,000	-76,000	-72,000	-75,000	-79,000	-77,000	-76,000	-75,000	-65,000	-66,000	-72,000	-63,000	-52,000	-66,000	-50,000	-300,055,000	-49,000	-74,000	-124,000	-129,000	-142,000	-225,000	-220,000	-247,000
payments of contingent consideration															0	0			-1,643,000	-459,000	0	-1,265,000	0	-1,044,000	0	-1,433,000	0	-808,000	0	-1,270,000	0	-576,000	0	-3,105,000	0	0	0	-3,500,000	0	0	0	-2,983,000					0
cash, cash equivalents and restricted cash at beginning of year
cash, cash equivalents and restricted cash at end of year
payments for investment in loan receivable
net decrease in cash, cash equivalents and restricted cash
recovery of (payments for) purchases of intangible assets																							1,435,000	0	-20,000	7,403,000
proceeds from issuance of common stock under the employee stock purchase plan and upon exercise of stock options														4,177,000
recovery of purchases of intangible assets
payments for investment in loan instrument
payments for credit agreement renewal fees																							0	-28,000
proceeds from issuances of common stock for share-based compensation															6,172,000	6,353,000	4,055,000	4,052,000	5,017,000	6,979,000	4,134,000	4,068,000	3,373,000	5,828,000			12,137,000	-1,278,000					-112,000	3,890,000	2,452,000	1,953,000	3,107,000	3,768,000
proceeds from reissuances of treasury stock for shared-based compensation
capital expenditures																-34,628,000	-23,388,000	-19,547,000	-39,235,000	-19,978,000	-18,116,000	-21,591,000	-21,598,000	-31,091,000	-22,214,000	-23,629,000	-53,874,000	-22,054,000	-26,713,000	-27,184,000	-26,068,000	-20,313,000	-25,619,000	-39,332,000	-45,113,000	-39,458,000	-31,569,000	-25,296,000	-27,987,000	-24,744,000	-32,189,000	-27,080,000	-40,134,000	-19,973,000	-34,960,000	-25,932,000	-29,642,000	-24,758,000	-24,495,000	-34,103,000	-40,051,000	-36,669,000	-41,043,000	-34,654,000	-35,655,000	-24,676,000
free cash flows																195,735,000	131,236,000	94,063,000	245,499,000	115,686,000	74,006,000	41,217,000	138,204,000	68,659,000	133,188,000	19,314,000	51,135,000	40,223,000	51,149,000	13,162,000	43,286,000	8,018,000	36,801,000	-95,552,000	50,006,000	12,149,000	45,586,000	-32,744,000	7,965,000	57,535,000	6,344,000	2,366,000	82,000	63,299,000	45,943,000	42,989,000	43,799,000	38,089,000	-5,807,000	-13,603,000	58,603,000	34,673,000	32,599,000	606,000	42,922,000	26,482,000
net increase in cash, cash equivalents, and restricted cash																127,359,000	59,457,000	10,589,000		232,969,000	3,689,000	-54,208,000		-20,016,000	124,831,000	24,373,000		31,504,000	-3,560,000	22,662,000
cash, cash equivalents, and restricted cash at beginning of period																0	0	667,115,000		0	0	662,651,000		0	0	434,164,000		0	0	384,983,000
cash, cash equivalents, and restricted cash at end of period																127,359,000	59,457,000	677,704,000		232,969,000	3,689,000	608,443,000		-20,016,000	124,831,000	458,537,000		31,504,000	-3,560,000	407,645,000
(payments for) proceeds from forward foreign exchange contracts																																			7,277,000	-2,847,000	-2,725,000	-2,869,000							-30,000	-1,325,000
investment proceeds and miscellaneous receipts																			5,152,000	10,244,000	2,180,000	3,912,000	3,581,000	3,999,000	19,597,000	4,496,000	4,782,000	3,247,000	16,196,000	2,158,000	4,429,000	1,516,000	12,289,000	1,658,000	1,323,000	1,550,000	11,143,000	1,667,000	2,258,000	1,035,000	7,485,000	1,175,000	4,308,000	1,080,000	9,000,000	1,283,000	3,834,000	2,000,000	8,941,000	1,985,000	3,563,000	1,598,000	7,221,000	609,000	1,562,000	1,719,000
(payments for) proceeds from acquisitions, net of cash received																								-59,728,000
(payments for) recovery of purchases of intangible assets																				0	0	-100,000
proceeds from reissuances of treasury stock for share-based compensation																								0	0	3,831,000
proceeds from divestiture of a product line																											0	45,000	0	6,919,000
(payments for) proceeds from acquisitions and long-term investment
payments for purchases of restricted investment
net payments on line-of-credit arrangements and notes payable																																0	0	-36,000										-300,000	-12,000	-50,000	66,000				22,000				-3,869,000
excess tax benefits from share-based compensation																																			-412,000	-1,019,000	-8,000	-67,000	-368,000	-1,984,000	-46,000	-1,212,000	-583,000	-298,000	-286,000	-182,000	-1,912,000	-309,000	-393,000	-106,000	-1,964,000	-376,000	-208,000	-341,000	-1,138,000	-259,000
proceeds from (payments for) acquisitions and long-term investment
net (payments) borrowings on line-of-credit arrangements and notes payable
proceeds from (payments for) acquisitions and long-term investments																												0
interest (paid) received																														-378,000								-187,000
payments for forward foreign exchange contracts																														-4,358,000		-8,005,000	-600,000	-7,429,000
payments for acquisitions and long-term investments																																-1,301,000	-32,000	-73,541,000
proceeds from issuances of common stock																														3,872,000
payments for acquisitions and long-term investment
net increase in cash and cash equivalents																																			38,325,000	-712,000	15,036,000	-53,934,000	-49,780,000	57,196,000	24,405,000	12,477,000	-11,342,000	39,923,000	20,163,000	32,956,000
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
net decrease in cash and cash equivalents																																7,310,000	29,921,000	-164,601,000													39,758,000	-75,206,000	-1,630,000	-94,759,000		-30,030,000	-77,325,000	-40,419,000		727,000
cash and cash equivalents at beginning of period																																0	0	456,264,000		0	0	457,549,000		0	0	413,251,000		0	0	331,551,000		0	0	463,388,000		0	0	574,231,000		0
cash and cash equivalents at end of period																																7,310,000	29,921,000	291,663,000		-712,000	15,036,000	403,615,000		57,196,000	24,405,000	425,728,000		39,923,000	20,163,000	364,507,000		-75,206,000	-1,630,000	368,629,000		-30,030,000	-77,325,000	533,812,000		727,000
reconciliation of net income to net cash from operating activities:
net income																																27,393,000	5,035,000	12,413,000		18,405,000	18,014,000	12,276,000		17,370,000	28,423,000	17,818,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization																																35,363,000	37,026,000	33,662,000		38,488,000	37,578,000	34,090,000		33,561,000	32,126,000	32,283,000		37,122,000	36,336,000	36,671,000		36,970,000	34,921,000	33,290,000		32,136,000	31,653,000	31,096,000		30,384,000
share-based compensation																																6,035,000	5,186,000	5,393,000		4,911,000	4,762,000	4,645,000		4,004,000	4,234,000	4,071,000		3,332,000	3,681,000	3,701,000		3,113,000	3,299,000	3,482,000		2,922,000	3,190,000	3,136,000		2,512,000
losses (gains) on dispositions of securities																																-86,000						229,000							216,000	100,000
losses on dispositions of fixed assets
changes in fair value of contingent consideration																																-3,024,000	700,000	-9,400,000		-291,000	-589,000	-1,284,000		-825,000	1,287,000	-1,192,000		-3,039,000	-446,000	-4,893,000		-46,000	-590,000	-711,000
increase in accounts receivable																																-20,578,000
increase in inventories																																-18,350,000	-11,006,000	-26,864,000		-16,959,000	-16,579,000	-34,400,000		-21,025,000	-17,115,000	-29,469,000		-11,672,000	-5,780,000	-11,429,000		-20,069,000	-18,743,000	-18,350,000		-2,154,000	207,000	-15,502,000		-20,509,000
increase in other current assets																																-3,856,000	4,277,000	-19,155,000		543,000	13,169,000	-15,730,000			3,856,000	-5,076,000			8,030,000	-11,390,000		60,000	3,660,000	-9,468,000		4,347,000	-4,097,000	-4,617,000		8,472,000
decrease in accounts payable and other current liabilities																																5,022,000	36,995,000	-61,155,000			15,102,000	-47,666,000											-2,111,000	-8,725,000		-744,000	2,608,000	-7,780,000		-3,530,000
decrease in income taxes payable																																																-1,361,000	-18,624,000	-10,725,000				-10,436,000
increase in deferred income taxes																																5,349,000	-2,894,000	-163,000		-12,540,000
net decrease/increase in other long-term assets/liabilities																																3,521,000	6,913,000	3,984,000		28,000	3,929,000	6,393,000		1,268,000	-4,056,000	-1,489,000		10,906,000	-2,585,000	1,167,000
increase in income taxes payable																																	-11,553,000	-1,655,000		-8,434,000	-14,064,000	14,075,000		-2,092,000	10,746,000	6,106,000			11,927,000	1,621,000						-12,865,000				-5,502,000
interest received (paid)																																		329,000								471,000
income tax (payments) refunds																																		-8,804,000
(gains) losses on dispositions of securities																																		-126,000						53,000	142,000	-214,000										-1,136,000	-132,000	-6,247,000
decrease in accounts receivable																																		6,846,000		583,000	12,076,000	19,991,000		7,137,000	-5,708,000	15,567,000				39,569,000				14,454,000		4,952,000	2,346,000	17,582,000
settlement with the sec and doj relating to the fcpa, including interest
payments for acquisition and long-term investment																																			-2,380,000	-308,000	-1,843,000	-9,634,000
net borrowings (payments) on line-of-credit arrangements and notes payable
debt issuance costs on long-term borrowings																																																							0	0
net borrowings from line-of-credit arrangements and notes payable
gains on dispositions of securities																																				-27,000													87,000	-190,000
increase in accounts payable and other current liabilities																																										-7,747,000				7,318,000
income tax refunds																																						10,421,000				1,503,000
payments for acquisitions, net of cash received, and long-term investments																																							-866,000	-901,000			-982,000	-1,635,000	-40,646,000	-1,364,000	-3,544,000	10,873,000	-4,327,000	-75,056,000	-964,000	-19,890,000	-3,260,000	-15,329,000	-149,840,000	-3,470,000
payment for purchase of restricted investment
proceeds from issuance of common stock																																							3,510,000	140,000	3,080,000	1,506,000	6,686,000	1,892,000	3,049,000	3,424,000	1,840,000	2,817,000	3,445,000	3,135,000	1,653,000	2,746,000	2,748,000	3,464,000	1,218,000	2,573,000
net borrowings from (payments for) line-of-credit arrangements and notes payable
payments of debt issuance costs for credit agreement																																												-61,000
decrease in other current assets
payments for purchases of long-term investments																																										-895,000
purchase of treasury stock																																																			0	0
reconciliation of net income including noncontrolling interests to net cash from operating activities:
net income including noncontrolling interests																																												11,509,000	31,631,000	6,668,000		-6,519,000	34,674,000	19,520,000		42,371,000	48,565,000	30,944,000		45,862,000
adjustments to reconcile net income including noncontrolling interests to net cash from operating activities:
losses on dispositions of securities
decrease (increase) in other current assets
decrease (increase) in accounts receivable																																																								-1,033,000
adjustments to reconcile net income including noncontrolling interests to net cash from operating activities excluding the effects of acquisitions:
forward foreign exchange contracts
net increase in other long-term liabilities
proceeds from foreign currency exchange contracts
net (payments for) borrowings from line-of-credit arrangements and notes payable																																																	1,000	-19,000
foreign currency exchange contracts
other																																																	4,488,000	1,972,000		13,251,000	-1,421,000	-3,985,000		1,710,000
proceeds from sales of property, plant and equipment																																																		26,000		117,000
proceeds from (payments for) foreign currency economic hedges																																																		3,943,000
foreign currency economic hedges																																																		-3,943,000		4,622,000	-4,614,000	1,410,000		-6,949,000
proceeds from sale of property, plant and equipment																																																							57,000	63,000
payments on purchases of intangible assets																																																						-245,000	3,000	-296,000
purchases of marketable securities and investments																																																						-185,468,000	-126,552,000	-144,774,000
sales of marketable securities and investments																																																						27,721,000	1,107,000	4,391,000
maturities of marketable securities and investments																																																						123,100,000	134,856,000	106,000,000
(payments for) proceeds from foreign currency economic hedges																																																								6,949,000
restricted cash
long-term borrowings
payments for foreign currency economic hedges																																																						-1,410,000
net borrowings on line-of-credit arrangements and notes payable																																																					87,000	139,000
miscellaneous receipts (payments)
payments for acquisitions, net of cash received,
and long-term investments
sales and maturities of marketable securities
and investments
proceeds from (payments for) foreign currency
economic hedges
net payments on line-of-credit arrangements and
notes payable
non-cash investing activities:
capital lease obligation for facilities
purchased intangible assets

We provide you with 20 years of cash flow statements for Bio-Rad Laboratories stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Bio-Rad Laboratories stock. Explore the full financial landscape of Bio-Rad Laboratories stock with our expertly curated income statements.

The information provided in this report about Bio-Rad Laboratories stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.